Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
